Mal-PEG4-bis-PEG3-methyltetrazine Catalog number: BADC-01275

Mal-PEG4-bis-PEG3-methyltetrazine is a highly functionalized compound used in advanced bioconjugation and targeted drug delivery applications. This compound features a maleimide (Mal) group, a polyethylene glycol (PEG4) spacer, a bis-PEG3 linker, and a methyltetrazine moiety. The maleimide group is highly reactive with thiol groups, allowing for stable covalent bonding with biomolecules such as antibodies, peptides, or proteins. The PEG spacers provide solubility, reduced immunogenicity, and enhanced pharmacokinetics, making it an ideal candidate for in vivo applications. The methyltetrazine group is useful for bioorthogonal chemistry, enabling selective conjugation or activation in complex biological environments. This compound is widely used in targeted cancer therapies and imaging applications.

A primary application of Mal-PEG4-bis-PEG3-methyltetrazine is in the development of antibody-drug conjugates (ADCs) for cancer treatment. By attaching cytotoxic drugs or imaging agents to antibodies via the maleimide group, the compound ensures targeted delivery to cancer cells that express specific surface markers. The PEG4 spacer improves solubility and stability in circulation, enhancing the pharmacokinetics of the conjugate. The bis-PEG3 linker further increases flexibility, allowing for more efficient drug delivery. The methyltetrazine group enables bioorthogonal reactions, such as the Staudinger ligation or tetrazine-trans-cyclooctene reactions, which can be used for precise drug release in the tumor microenvironment or for imaging. This targeted approach minimizes off-target effects and increases the therapeutic index of the drug.

Mal-PEG4-bis-PEG3-methyltetrazine is also employed in bioorthogonal chemistry for selective labeling and imaging of biomolecules. The methyltetrazine group can react with trans-cyclooctene (TCO) or other tetrazine-based reagents in living systems, allowing for the covalent labeling of specific proteins, peptides, or nucleic acids without interference from natural functional groups. This selective reactivity makes it an excellent tool for labeling in vivo, enabling real-time imaging and tracking of biomolecules in living organisms. The PEG spacers ensure that the labeled molecules maintain their solubility and native structure, which is critical for accurate imaging and analysis. This application is particularly valuable in molecular imaging, proteomics, and studying cellular interactions.

Furthermore, Mal-PEG4-bis-PEG3-methyltetrazine is utilized in the development of targeted delivery systems for other therapeutic agents, including small molecule drugs and RNA-based therapies. The bioorthogonal reactivity of the methyltetrazine group allows for the controlled release of drugs at specific sites within the body. This feature is particularly beneficial for overcoming challenges such as poor tissue penetration and off-target toxicity associated with traditional drug delivery methods. The PEG spacers enhance the overall stability and solubility of the conjugate, improving its effectiveness in vivo. By enabling precise drug activation or release at the target site, this compound offers significant potential in advancing targeted therapies, particularly for diseases such as cancer and genetic disorders.